As the addition of αPD1 can further block the PD1/PDL1 signaling axis between tumor and immune cells, the combination of VSV-S and PD1-based immunotherapy deserves to be further investigated as a novel strategy for achieving more effective and durable antitumor effects. Here, CD274 is linked to neoplasm.